Literature DB >> 23657824

Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.

David Martin1, David Menschik, Marthe Bryant-Genevier, Robert Ball.   

Abstract

BACKGROUND: Reports of data mining results as an initial indication of a prospectively detected safety signal in the US Vaccine Adverse Event Reporting System (VAERS) have been limited. In April 2010 a vaccine safety signal for febrile seizures after Fluvax(®) and Fluvax(®) Junior was identified in Australia without the aid of data mining. In order to refine Northern Hemisphere influenza vaccine safety surveillance, VAERS data mining analyses based on vaccine brand name were initiated during the 2010-2011 influenza season.
OBJECTIVE: We describe the strategies that led to the finding of a novel safety signal using empirical Bayesian data mining.
METHODS: The primary US VAERS analysis calculated an empirical Bayesian geometric mean (EBGM), which was adjusted for age group, sex and year received. A secondary age-stratified analysis calculated a separate EBGM for 11 pre-defined age subsets. These bi-weekly analyses were generated with database restrictions that separated live and inactivated vaccines as well as with the US VAERS database. A cutoff of 2.0 at the fifth percentile of the confidence interval (CI) for the EBGM, the EB05, was used to identify vaccine adverse event combinations for further evaluation. Examination of potential interactions among concomitantly administered vaccines is based on the Interaction Signal Score (INTSS), which is a relative measure of how much excess disproportionality is present in the three-dimensional combination of two vaccines and one adverse event term. An INTSS >1 indicates that the CI for the three-dimensional analysis is larger than and does not overlap with the CI from the highest two-dimensional analysis. We subsequently examined the possibility of masking by removing all 2,095 Fluzone(®) 2010-2011 reports from the 10 December 2010 version of the VAERS database. In addition, we calculated relative reporting ratios to observe the relative contribution of adjustment and the Multi-Item Gamma Poisson Shrinker (MGPS) algorithm to EBGM values.
RESULTS: On 10 December 2010, US VAERS analyses we found an EB05 >2 for Fluzone(®) 2010-2011 and the Medical Dictionary for Regulatory Activities (MedDRA(®)) term "febrile seizure". MedDRA(®) terminology is the medical terminology developed under the auspices of the International Conference on Harmonization of technical requirements for Registration of Pharmaceuticals for Human Use (ICH). No other vaccine products had independent vaccine-febrile seizure combinations with an EB05 >2. Three-dimensional analyses to examine possible interactions among vaccine products concomitantly administered with Fluzone(®) 2010-2011 yielded Interaction Signal Score values <1. Removal of all Fluzone(®) 2010-2011 reports from the VAERS database failed to demonstrate a previously masked vaccine adverse event pair with an EB05 >2. The inactivated vaccine database restriction resulted in a 41 % reduction in background VAERS reports and a 24 % reduction in foreground VAERS reports.
CONCLUSION: Empirical Bayesian data mining in VAERS prospectively detected the safety signal for febrile seizures after Fluzone(®) 2010-2011 in young children. The EB05 threshold, database restrictions, adjustment and baseline data mining were strategies adopted a priori to enhance the specificity of the 2010-2011 influenza vaccine data mining analyses. A database restriction used to separate live vaccines resulted in a reduced EB05. Adjustment of data mining analyses had a larger effect on estimates of disproportionality than the MGPS algorithm. Masking did not appear to influence our findings. This case study illustrates the value of VAERS data mining for vaccine safety monitoring.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23657824     DOI: 10.1007/s40264-013-0051-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  21 in total

1.  Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination.

Authors:  M T Niu; D E Erwin; M M Braun
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

2.  Photophobia following smallpox vaccination.

Authors:  A W McMahon; M C Bryant-Genevier; E J Woo; M M Braun; R Ball
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

3.  Comparing data mining methods on the VAERS database.

Authors:  David Banks; Emily Jane Woo; Dale R Burwen; Phil Perucci; M Miles Braun; Robert Ball
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-09       Impact factor: 2.890

4.  Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

Authors:  June S Almenoff; Karol K LaCroix; Nancy A Yuen; David Fram; William DuMouchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Thrombocytopenia after vaccination: case reports to the US Vaccine Adverse Event Reporting System, 1990-2008.

Authors:  Emily Jane Woo; Robert P Wise; David Menschik; Sean V Shadomy; John Iskander; Judy Beeler; Frederick Varricchio; Robert Ball
Journal:  Vaccine       Date:  2010-11-30       Impact factor: 3.641

6.  Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-03-12       Impact factor: 17.586

7.  Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-13       Impact factor: 17.586

8.  Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.

Authors:  Manette T Niu; Robert Ball; Emily Jane Woo; Dale R Burwen; Maureen Knippen; M Miles Braun
Journal:  Vaccine       Date:  2008-11-06       Impact factor: 3.641

9.  Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

Authors:  Barbara A Slade; Laura Leidel; Claudia Vellozzi; Emily Jane Woo; Wei Hua; Andrea Sutherland; Hector S Izurieta; Robert Ball; Nancy Miller; M Miles Braun; Lauri E Markowitz; John Iskander
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

Review 10.  Novel statistical tools for monitoring the safety of marketed drugs.

Authors:  J S Almenoff; E N Pattishall; T G Gibbs; W DuMouchel; S J W Evans; N Yuen
Journal:  Clin Pharmacol Ther       Date:  2007-05-30       Impact factor: 6.875

View more
  10 in total

1.  Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Authors:  Lakshmi Sukumaran; Michael M McNeil; Pedro L Moro; Paige W Lewis; Scott K Winiecki; Tom T Shimabukuro
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

2.  Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.

Authors:  Pedro Moro; Jane Baumblatt; Paige Lewis; Janet Cragan; Naomi Tepper; Maria Cano
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

3.  Safety of the 9-Valent Human Papillomavirus Vaccine.

Authors:  Tom T Shimabukuro; John R Su; Paige L Marquez; Adamma Mba-Jonas; Jorge E Arana; Maria V Cano
Journal:  Pediatrics       Date:  2019-11-18       Impact factor: 7.124

Review 4.  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).

Authors:  Tom T Shimabukuro; Michael Nguyen; David Martin; Frank DeStefano
Journal:  Vaccine       Date:  2015-07-22       Impact factor: 3.641

5.  Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Authors:  Pedro L Moro; Janet Cragan; Paige Lewis; Lakshmi Sukumaran
Journal:  Birth Defects Res       Date:  2017-07-17       Impact factor: 2.344

Review 6.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

7.  Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015.

Authors:  Pedro L Moro; Emily Jane Woo; Wendy Paul; Paige Lewis; Brett W Petersen; Maria Cano
Journal:  PLoS Negl Trop Dis       Date:  2016-07-13

Review 8.  Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.

Authors:  Penina Haber; Pedro L Moro; Paige Lewis; Emily Jane Woo; Christopher Jankosky; Maria Cano
Journal:  Vaccine       Date:  2016-03-23       Impact factor: 3.641

9.  Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia.

Authors:  Hazel J Clothier; Jock Lawrie; Melissa A Russell; Heath Kelly; Jim P Buttery
Journal:  PLoS One       Date:  2019-11-01       Impact factor: 3.240

10.  A bibliometric analysis and visualization of medical data mining research.

Authors:  Yuanzhang Hu; Zeyun Yu; Xiaoen Cheng; Yue Luo; Chuanbiao Wen
Journal:  Medicine (Baltimore)       Date:  2020-05-29       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.